Due Care and Unintentionality Criteria for the reinstatement of Priority Rights

Patent priority rights play a pivotal role in the protection process for inventions, however, securing and maintaining such priority rights can be complex. Patent applicants can find themselves unintentionally losing the priority right to their invention due to unforeseen circumstances, and whilst it may not be ideal, there are solutions that could lead to their reinstatement in certain situations.

Application

Patent priority rights grant applicants an exclusive right to file for patent protection for their invention based upon an earlier application filed by the applicant. Priority rights are facilitated in multiple areas through international treaties such as the Paris Convention and the Patent Cooperation Treaty (PCT), for example.

Some jurisdictions allow for the reinstatement of patent priority rights if the failure to meet deadlines and subsequent lapse of priority was due to "due care", or if the lapse of priority was due to "unintentionality." These jurisdictions typically include countries that adhere to the Paris Convention for the Protection of Industrial Property, however, specific criteria and procedures for reinstatement vary by jurisdiction. Due to the nuanced nature of priority restoration, it is crucial to consult the patent laws and regulations of each country for detailed information on the requirements and process for reinstatement of priority rights.

As per the PCT, in instances whereby a patent application possesses an international filing date later than the date the priority period lapsed, the applicant may request restoration of priority if done so within two months from the initial expiration date and if the Office finds that the correct criteria apply.

Grounds for reinstatement

Due Care

One available route for the restoration of priority is by applying for reinstatement based upon due care criteria. In the sphere of patent priority rights, due care refers to the level of responsibility and diligence expected from patent applicants in managing their applications and complying with relevant regulations and obligations. There are generally strict criteria which must be met in order to obtain reinstatement of a priority right via due care grounds.

If a lapse of priority is deemed to have occurred in spite of due care that a “reasonably prudent applicant would have taken” in the patent application process, the priority rights may be restored for an applicant by an IP Office.

In order to meet the standards for due care criteria for the reinstatement of priority rights, patent applicants must demonstrate that they have met a series of high standards as it is not sufficient for an applicant to simply demonstrate that they had generally taken precautions to adhere to time limits, for example.

Instead, the applicant should demonstrate that they exercised complete due care for the entire application, with the Receiving Office assessing all factual elements of the applicant's actions pertaining to the filing of the international application up to the expiration of the priority period. Any actions taken by the applicant after the expiration of the priority period will not be taken into consideration when determining whether the applicant took all actions necessary to demonstrate due care.

Due Care Criteria

The criteria that will typically be examined by an IP Office in order to establish that an applicant took all due care in order to reinstate a priority right include:

1. Lack of Knowledge by the Applicant
2. Lack of Financing by the Applicant
3. Human Error by the Applicant or Agent Himself
4. Miscommunication between the Applicant and the Agent
5. Absence from the Office by the Applicant or Agent
6. Human Error by the Agent’s or Applicant’s Staff
7. Docketing System Error
8. Facsimile or Software Submission Failure
9. Postal Service Difficulties
10. Force Majeure

The IP Office will factually analyze each of these criteria in accordance with the requirements and in comparison to what actions they would deem a “prudent applicant” would have made in order to have complied with the due care criteria.

Unintentionality

The Unintentionality Criterion is another possible route for the reinstatement of priority rights, and overall the requirements for the meeting of such criteria are less stringent than those needed to prove due care was taken by an applicant.

Overall, a Receiving Office should restore a priority right if it is found that any failings on behalf of the applicant to file the international application within the set priority period was unintentional. In order to meet this criteria, an applicant must be able to demonstrate that they did not deliberately refrain from filing the international application within the priority period and that they had every underlying intention to file within the priority period.

Unintentionality Criteria

Some of the most common circumstances that apply for the unintentionality ground for reinstatement of priority include:

1. Lack of awareness
2. Misunderstanding of the law
3. Reliance on incorrect information

In essence, the focus on whether the applicant should meet the unintentionality criteria or not should lay upon the Receiving Office’s assessment as to the applicant's intent at the expiration of the priority period, regardless of their intent before or after the priority period.

Statement of Reasons

Whether an applicant intends to rely on the due care or the unintentionality criteria in order to apply for the reinstatement of priority rights, the applicant is required to set forth to the Receiving Office the reasons why the application was not filed within the established period. These reasons should be submitted in the form of a “Statement of Reasons.”

With regard to said statement in relation to the due care criterion, it should contain a detailed description of all facts and circumstances that amounted to the late filing of the international application past the priority expiration. Further, the statement of reasons in relation to due care grounds for reinstatement should also depict any remedial steps or alternative remedies that the applicant sought in an attempt to file the application within the priority period.

If the grounds for reinstatement are based upon the unintentionality criterion, the statement of reasons should detail that any failure to comply and submit the international application within the assigned priority period was entirely not intentional. Should the Receiving Office not find the statement of reasons sufficient, they may invite the applicant to submit a revised statement.

Moreover, supporting evidence will assist alongside the Statement of Reasons in demonstrating that the lapse of priority for an applicant should be reinstated based on either the due care criteria, or the unintentionality criteria.

Overall, reinstatement of priority owing to grounds of due care is a more strict criterion that focuses on the proactive measures taken by individuals or entities to prevent intellectual property infringement, whilst the unintentionality criterion is typically more flexible.

In amongst the nuances of priority reinstatement regulations, there is hope for applicants who may have lost patent priority rights. If you are interested in learning more about the possibilities of reinstating patent priority rights, or if you would like our assistance with your matter, contact us via our social media or website at https://www.ip-coster.com!

欧亚专利局
2024 二月 28 14:00:00

欧亚专利局(EAPO)成立于1995年,是一个政府间组织,以《欧亚专利公约》(EPC)为准则,旨在促进该地区知识产权的保护和发展。EPC于1994年9月9日首次签署,次年8月12日生效,标志着EAPO正式成立。

EAPO的成员国包括独联体国家(CIS)和非独联体国家,有助于促进知识产权领域的国际合作。截至2024年,成员国包括亚美尼亚、阿塞拜疆、白俄罗斯、哈萨克斯坦、吉尔吉斯斯坦、俄罗斯、塔吉克斯坦和土库曼斯坦。EAPO总部位于俄罗斯,官方语言为俄语。

EAPO的主要目标是通过在8个成员国提交一件欧亚申请,推动发明和外观设计相关的知识产权保护。因此,在简化欧亚地区知识产权申请流程中,EAPO起着至关重要的作用,为发明人和企业提供了一个统一的平台,为其同时在多个成员国寻求知识产权的保护提供了可能性。因此,EAPO体系有助于简化申请发明和外观设计保护的流程,削减开支,提高效率,从而促进该地区创新和技术的发展。

欧亚专利局成立初始即致力于保护欧亚专利,并在2019年通过《欧亚专利公约工业品外观设计保护议定书》后,于2021年6月开始受理区域外观设计保护的申请。

如要在EAPO成员国获得欧亚专利,申请人仅需向EAPO提交一件申请,不限语言,但需在之后2个月内递交其俄文译本。如已缴纳相应费用,此期间可延长至4个月。也可通过PCT申请进入欧亚地区获得欧亚专利,应自最早优先权日起31个月内。欧亚专利申请应申请人请求进行实质审查。巴黎公约进欧亚,应自检索报告公布之日起6个月内提交实审请求;PCT进欧亚,应在进入欧亚地区时同时提交实质审查请求。

授权欧亚专利后,专利权人可选择需缴纳维持费的成员国以及恢复因未缴纳维持费而失效的欧亚专利。在部分发明领域,申请人也可要求延长欧亚专利的有效期。自欧亚专利公布之日起至缴纳首次年费期间,专利权人对其发明专利在欧亚地区有独占权。

需直接向EAPO缴纳欧亚发明或外观设计专利相关费用,而非单独缴纳至各个成员国。如提供国际检索报告或由其他国际检索单位(ISA)开具的PCT检索报告,可减缴25%的欧亚专利申请费。如此类报告由俄罗斯联邦知识产权局开具,可减缴40%的申请费。

自2022年起,以《专利合作协定》(PCT)为准则,EAPO成为国际检索单位(ISA)以及国际初审单位(IPEA)。

EAPO积极参加多项国际合作,包括与非洲知识产权组织(OAPI)、非洲地区知识产权组织(ARIPO)、欧盟知识产权局(EUIPO)、欧洲专利局(EPO)以及世界知识产权组织 (WIPO) 签署《谅解备忘录》(MoU's)。

此外,EAPO还与日本专利局(JPO)、韩国知识产权局(KIPO)、芬兰专利注册局(PRH)以及EPO在内的全球多家知识产权局开展专利审查高速路项目。通过与签署PPH协议的各个知识产权局共享审查结果,加快了整个专利申请流程。

EAPO致力于知识产权保护,为该地区的研究、发展和经济增长创造了一个良好的环境。如您想了解在欧亚或通过EAPO申请知识产权保护的更多信息,请通过社交平台联系我们或 点击此处!

 

翻译:徐晨星

欧盟知识产权局
2024 二月 05 14:00:00

欧盟知识产权局(EUIPO)成立于1994年,是一个地区性的知识产权局和欧盟机构,总部位于西班牙阿利坎特。因此,EUIPO致力于保护欧盟商标(EUTM),过去称之为“欧共体商标”,以及注册共同体外观设计(RCD)。EUIPO还有一个法语名称,即Office de l'Union européenne pour la propriété intellectuelle。

EUIPO根据欧洲议会和理事会于2017年6月14日制定的关于欧盟商标2017/1001号条例(EU)成立和运作。作为知识产权相关事务的国际中心,EUIPO使用5种工作语言,即英语、法语、德语、意大利语和西班牙语。EUIPO受理的申请可用欧盟23种官方语言处理。

注册共同体外观设计以及通过EUIPO注册的欧盟商标可在所有欧盟成员国享受统一保护效力。EUIPO会公布注册的商标和外观设计并在所管理的相应知识产权登记簿中披露相关信息。欧盟商标登记簿通常包括所有欧盟商标申请和注册的详细信息,而欧盟外观设计登记簿常含有已注册的欧盟外观设计相关信息。这两个登记簿会持续更新,跟进欧盟商标或注册式欧盟外观设计的修改,例如所有权信息和许可。

此外,EUIPO还向公众发布包括上述注册信息的《欧盟商标公告》和《欧盟外观设计公告》以及其他相关信息。

EUIPO不但致力于优化欧盟外观设计和欧盟商标的注册流程,还对孤儿作品数据库进行维护,提供会员国教育机构和档案库等公开渠道内的孤儿作品相关信息的访问渠道。

此外,EUIPO还负责监督知识产权侵权观察站,旨在通过鼓励良好的职业操守和合作规范来提高公众意识,从而协助打击假冒和盗版行为。自2012年起,EUIPO开始监督孤儿作品和侵权观察站。

EUIPO每年审查超15万件欧盟商标和9万件欧盟外观设计的申请,对促进欧盟地区的知识产权发展起着至关重要的作用。此外,EUIPO开展了全球范围内诸多国际合作和倡议,符合欧盟委员会对外政策的优先策略。例如,EUIPO致力于帮助人们认识到知识产权保护和注册的益处,鼓励创新,不断推进欧洲经济发展。

此外,EUIPO通过推进立法现代化和积极加入各类国际知识产权条约,推动知识产权管理和执法服务发展。通过谅解备忘录(MoU),EUIPO和其他知识产权局达成直接合作,确立了有利于欧盟成员国乃至全球知识产权领域的行动。

EUIPO还加入了商标五局(TM5)(商标5大知识产权局)和外观设计五局(ID5)(外观设计的5大知识产权局)。这5个知识产权局与世界知识产权组织(WIPO)保持着紧密的合作,分别是CNIPA(中国国家知识产权局)、EUIPO(欧盟知识产权局)、JPO(日本专利局)、KIPO(韩国知识产权局)和USPTO(美国专利商标局)。

EUIPO不仅仅是欧洲知识产权领域的焦点,也是其他地区知识产权保护的焦点。

 

翻译:徐晨星

委托书
2022 十月 04

委托书,通常缩写为POA,是一种法律文件,为一方代表或代理另一方处理某些事务或事项所出具的书面授权。此类事项包括法律诉讼、企业和商业事项,以及甚至个人事务,例如持久委托书(LPA).

具体到知识产权时,很多申请人和权利人选择,或基于适用的国家或地区知识产权法的规定,任命一位法律代表或代理作为代表申请人行事的第三方。

此类法律代表可以是专利代理人,例如,在相关国家或地区的知识产权局和/或法庭,就所委任的专利事项代表知识产权申请人或注册人。在这种情况下,委托书可作为代理人就申请人专利的申请和维持事项代表专利申请人的书面授权。

委托书也可用于在工作场所开发发明和专利相关的知识产权事务。当公司通过委托书来代表或获取员工在任职期间开发和创造的发明时,就会出现这种情况。

获得委托书以及提供用于知识产权事务的此类证明,各国要求都不一样。例如,针对委托书的使用,美国法律规定在本管辖区内,对获得委托书及其有效性有多项要求。

因此,在美国,一份针对法律实体的有效委托书应包括委托书签字日期、由委托人或在委托人在场并在其指示下有权签署文件的另一名成年人签字。此外,在美国,委托书必须在公证人面前签署确认或由两名证人签署。

除国内立法对获得委托书有所要求外,国家和地区法律还要求申请人和权利人遵守所提交或维持的知识产权所在知识产权局的规则。例如,在某些国家,委托书的代表或代理必须是知识产权提交或注册的管辖区内备案的代理人,但是这一规定并不适用于所有国家。

此外,很多管辖区要求提交一份文件,确认签署委托书的签字人可代表申请人就其知识产权获得申请日。一些国家还要求所提供的委托书必须为原件,且经公证和认证后才有效,但这并非适用于所有管辖区。

委托书是注册和维持知识产权的重要组成部分,往往也是至关重要的一部分。由于国际立法和要求有所不用,因此知识产权申请人和权利人应密切关注委托书签字和提交方面的必要要求,以便管理其知识产权组合。

 

商业秘密

商业秘密以多种形式存在,例如产品、工艺、实践等,且在以下三个条件下受保护:所述主题必须不为公众所知,不公开披露可带来经济效益,所有人必须确保其机密。只要不满足其中一点,则商业秘密不受保护。

当提交专利申请时,您有义务向公众分享您的发明。作为回报,您将被授予在某个时间段内享有独家使用您产品的权利,此外,您也可以将其许可给他人。

然而,如果您选择通过商业秘密来保护您的知识产权,则无需向公共分享您的发明,相反,不公开反而会带来利益。

与专利保护相比,商业秘密的主要好处在于没有授权费用,而专利授权过程相对昂贵。此外,商业秘密无有效期限制,而在大多数国家,专利有效期为20年。

唯一可以使用受商业秘密法保护的信息的人即那些未使用非法手段或违法行为自行发现“秘密”的人。例如,研究合法制造的产品并推算出其商业秘密的行为并不违反商业秘密法。

让我们来看看可口可乐公司。我们可以发现,该公司名下拥有多项专利,涉及瓶子外观、自动售货机、人造调味剂等。20年后,所有这些专利都会到期,信息可为公众所用。

但是,可口可乐的配方作为商业秘密已受保护长达100多年,并且会一直持续下去,除非有人想出相同的配方,但这几乎不可能。

熟知各国商业秘密保护是一项艰巨的任务。每个国家都有自己的规章制度,保护什么,怎么保护以及可用的补救措施,因此我们建议您咨询专业的知识产权律师来处理这类保护。

公共健康和药品专利

众所周知,创新至关重要,在社会中占据非常重要的地位。例如,药品发明可以拯救无数人的性命。2020年,疫苗成为最为热门的话题之一。药品专利对公众健康会产生重要影响,因此政策制定者必须衡量相较于发明对公众的可及性而言药品专利权的各项因素,但什么是药品专利呢?

药品专利和普通专利非常相似,授予专利权人使用发明的专有权,但在期限和许可方面存在些许差异。除自申请日起20年的基础期限外,超20个国家会授予药品专利补充保护证书(SPC),例如美国、英国以及部分欧洲经济区(EEA)的国家。这些国家下发SPC,可以进行延期,提供自首次上市许可(MA)之日起最长15年的专有权或专利到期后额外提供5年的保护期,旨在弥补发明人在专利授权后和上市许可前损失的时间。

在英国,SPC不会延长专利期限,但是会提供类似的保护,在专利到期后生效,最长持续5年。如经过充分的儿科测试,药物活性成分的SPC也可延长6个月。值得注意的是,英国脱欧后,可能会发生变化。

美国也有类似的制度,但是专利期限延长证书适用于该管辖区内所有专利。此外,符合延期条件的专利期限可延长至与经批准产品的监管审查期相等的时间。这段时间通常在下发专利证书之日后,但是在EEA,保护范围有所缩小,仅适用于专利产品的活性成分。

证书期限在某些情况下也会受限。例如,当专利期限已根据某个国家法律进行了相应延长。

虽然专利保护有助于增加药品研究资金,极大地推动了救生发明的进步,但是由于专利治疗的垄断性和相应成本的增加,这也会妨碍个人获取所需治疗。其中一个可行的补救措施是实施强制许可机制,即允许另一方在未得到药品专利权人明确同意的情况下进行专利产品生产或工艺。这类保护措施确保制药行业因其推动科学进步、促进公共健康而获得补偿,同时也防止垄断出现。然而,另一方面,批评者指出,公司会倾向于购买许可证,增加治疗成本,而非研发新药品,这会阻碍创新的发展。

药品专利权在更为广泛的公共健康上产生的社会伦理影响颇具争议,需要集中解决。只有结合政策改革、国家对制药行业的标准化资助、公司责任以及共同协作稳定药物治疗成本,才会建立公平可及的公共健康制度。

12